Pescadillo ribosomal biogenesis factor 1 and programmed death-ligand 1 in gastric and head and neck squamous cell carcinoma

doi:10.3748/wjg.v31.i19.106644

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-3) series.

Item

Count

PDF

HTML

Tables (1-3)

Sum=0

May 21, 2025 (publication date) through May 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. May 21, 2025; 31(19): 106644
Published online May 21, 2025. doi: 10.3748/wjg.v31.i19.106644

Pescadillo ribosomal biogenesis factor 1 and programmed death-ligand 1 in gastric and head and neck squamous cell carcinoma

Xiao-Nan Hu, Chun-Feng Li, Si-Meng Huang, Chun-Lei Nie, Rui Pang

Xiao-Nan Hu, Department of Head and Neck Radiotherapy Ward, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China

Chun-Feng Li, Department of Gastrointestinal Surgical Ward, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China

Si-Meng Huang, Chun-Lei Nie, Rui Pang, Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, Harbin 150081, Heilongjiang Province, China

Co-first authors: Xiao-Nan Hu and Chun-Lei Nie.

Author contributions: Hu XN, Li CF, Huang SM, and Nie CL contributed to the research design, data collection, data analysis, and paper writing; Pang R was responsible for the research design, funding application, data analysis, reviewing and editing, communication coordination, ethical review, copyright and licensing, and follow-up; All authors read and approved the final manuscript. Hu XN and Nie CL contributed equally to this work as co-first authors.

Institutional review board statement: The research was reviewed and approved by the Affiliated Cancer Hospital of Harbin Medical University.

Informed consent statement: All research participants or their legal guardians provided written informed consent prior to study registration.

Conflict-of-interest statement: No conflicts of interest were associated with this work.

Data sharing statement: No other data available.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Rui Pang, Deputy Director, Department of Head and Neck Surgery, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Harbin 150081, Heilongjiang Province, China. 3151@hrbmu.edu.cn

Received: March 7, 2025
Revised: April 7, 2025
Accepted: April 23, 2025
Published online: May 21, 2025
Processing time: 74 Days and 21.1 Hours

Core Tip

Core Tip: This study investigated the expression of pescadillo ribosomal biogenesis factor 1 (PES1) and programmed death-ligand 1 (PD-L1) in tumor tissues from patients with gastric cancer and head and neck squamous cell carcinoma. We found that both proteins exhibited significant positive expression rates (51.72% for PES1 and 58.62% for PD-L1) and were associated with clinical features such as TNM stage and lymph node metastasis. Our results suggest that PES1 and PD-L1 may play critical roles in tumor progression and immune escape, potentially serving as biomarkers for immune-targeted therapies.